This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Journal and News Scan
This is a compreshensive review on the experience with use of TEVAR in patients with Marfan syndrome, including durablity, complications, and timing, etc. Drs. Steinmetz and Cosellihe also discussed the role and trend of TEVAR in Marfan paitents with aortic disease.
TAVR vs. Surgery: A New Look at 1-Year Outcomes Among Moderate-Risk Patients with Severe, Symptomatic AS
Transcatheter aortic valve replacement (TAVR) is not inferior to surgical aortic valve replacement (SAVR) when it comes to all-cause mortality after one year. This is among moderate-risk patients with severe, symptomatic aortic stenosis (AS). According to a new analysis published in JAMA, a close comparison revealed that each treatment option is associated with certain benefits over the other.
A recent ISCHEMIA trial substudy is under scrutiny from surgeons for a discrepancy in data. This has rekindled concerns about reliance on the landmark trial data in the newest coronary revascularization guidelines. CTSNet recently recently published a webinar on this topic featuring leading CT surgeons around the globe.
Gripping vignette of a fatal case of renocardiac pathologies. The stills from the (sadly non-contrast) CTA are most interesting.
Minimally invasive mitral valve surgery versus conventional sternotomy mitral valve surgery: A systematic review and meta-analys
Meta-analysis of 119 studies (approx 38,000 patients) evaluating outcomes of minimally invasive mitral valve surgery with conventional sternotomy approach.
MMVS was associated with fewer days in hospital (RCT: MD: -2.2 days, 95% CI, [-3.7 to -0.8]; observational: MD: -2.4 days, 95% CI, [-2.7 to -2.1]). Observational studies suggested that MMVS reduced transfusion requirements with fewer units transfused per patient (MD: -1.2; 95% CI, [-1.6 to -0.9]) and fewer patients transfused (RR, 0.7; 95% CI, [0.6-0.7]). Observational data also suggested lower mortality with MMVS (RR, 0.6; 95% CI, [0.5-0.7], p < .001, I2 = 0%), but this was not corroborated by RCT data. The risk of postoperative mitral regurgitation (≥2+ or requiring re-intervention) did not differ between the two groups.
Thirty-Year Trends in Graft Survival After Heart Transplant: Modeled Analyses of a Transplant Registry
Data from Scientific Registry of Transplant Recipients was modeled over 30 years to evaluate temporal trends, as well as graft survival.
Among 56,488 primary adult heart recipients, we observed 5529 (9.8%) all-cause deaths and 1933 (3.4%) graft failure events within 6 months posttransplant. Prevalence of known recipient risk factors increased over time. Unadjusted modeling demonstrated a significant 30-year improvement in graft survival, averaging 2.6% per year (95% confidence interval, 2.4-2.9; P for trend < .001). After adjusting for population changes the 30-year trend remained significant and graft survival improved on average 3.0% per year (95% confidence interval, 2.6-3.3). Regression modeling identified multiple predictors of graft survival. Modeling 2 additional outcomes of 6-month mortality and 6-month graft failure produced similar results.
Minimally invasive coronary bypass versus percutaneous coronary intervention for isolated complex stenosis of the left anterior
Retrospective review (propensity-matched) comparing patients undergoing PCI vs minimally invasive CABG for complex LAD lesions.
Overall 9-year survival was not significantly different between patient groups both before and after propensity matching. Midterm mortality in the matched minimally invasive direct coronary artery bypass group was low, irrespective of patient risk profile. By contrast, advanced age (hazard ratio, 1.10; P = .012) and obesity (hazard ratio, 1.09; P = .044) predicted increased late death after drug-eluting stent percutaneous coronary intervention among matched patients. Patients who underwent minimally invasive direct coronary artery bypass were significantly less likely to require repeat left anterior descending revascularization than those who had percutaneous coronary intervention, both before and after propensity matching. Smaller stent diameter in drug-eluting stent percutaneous coronary intervention was associated with increased left anterior descending reintervention (hazard ratio, 3.53; P = .005).
Recommendations for intraoperative lymph node evaluation are uniform regardless of whether a primary tumor is clinical T1a or T2a according to TNM 8th edition for stage I non-small cell lung cancer (NSCLC). We quantified nodal disease risk in patients with T1a disease (≤1 cm).
Lack of prioritization of simulation activities is commonly reported by trainees for a variety of reasons, including time constraints and perceived translational benefit. These barriers become even more pronounced in low-income countries with limited healthcare resources, as the current era of simulation-based training often requires substantial investments of time, money, and teaching personnel [4,5].
A low-fidelity compact simulator with all necessary instruments and materials contained within a 12.5-inch toolbox was utilized by thirty general surgery residents from an academic medical center with instruction on how to perform two different vascular anastomoses. Participants were then sent an anonymized survey evaluating its practicality and helpfulness.
Further, as a global health equity initiative, current efforts include implementing a “make one locally, give one globally” approach, whereby training programs can assist in creating additional simulators and distributing them to partner surgical training programs in low- and middle-income countries.